The Brand Extending Intimacy With Natural Ingredients

3 years ago

Male Plus’s Unique Combination of Tribulus Terrestris, Maca Root, and Siberian Ginseng Is an Effective Alternative to Stronger Chemical Libido…

OXOS Medical Raises $23M Series A to Deliver “Radiology Department in a Box” to the Entire Healthcare Value Chain

3 years ago

Co-led by Parkway Venture Capital and Intel Capital, OXOS will leverage funds to expand into clinical, mobile, and home care…

JenaValve Appoints Ken MacLeod, Ph.D. to Board of Directors

3 years ago

IRVINE, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement…

Celularity Inc. Announces $6 Million Registered Direct Offering

3 years ago

FLORHAM PARK, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic…

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

3 years ago

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

3 years ago

ILAP Designation accelerates patient access and commercializationMIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”),…

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

3 years ago

Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or…

CytoDyn to Hold Webcast to Provide a Company Update

3 years ago

VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

3 years ago

Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a…

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

3 years ago

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company…